Pembrolizumab (Keytruda®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||06/12/2017|
|Rapid review completed||21/12/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended at the submitted price|
The HSE has approved reimbursement following confidential price negotiations – November 2018.